AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04322929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Oral Tablet
Description: Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
Study NCT03772262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution
Description: Oral syrup
Study NCT03772262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin Oral Tablet
Description: Oral tablet
Study NCT04279535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Ascorbic Acid
Description: Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
Study NCT04279535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Ascorbic Acid
Description: Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
Study NCT00475566 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dynalink®-E everolimus-eluting peripheral stent
Description: Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery
Study NCT00475566 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dynalink®-E, everolimus-eluting peripheral stent
Description: Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery
Study NCT00940758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP02
Description: Dose escalation: 50-100 mg/m2 biweekly
Study NCT01694056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy protein diet
Description: 4 weeks high protein diet (20 en%) with 25gr of soy protein per day
Study NCT01694056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: 4 weeks high mixed protein diet (20 en%)
Study NCT04265794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: H2GO!
Description: Child participants will participate in a 6-week behavioral intervention consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. Each week consisted of a 1-hour health session and a 1-hour narrative session (delivered on separate days). Child participants will also receive reusable water bottles and a pictorial intervention booklet, which includes worksheets and parent-child take-home activities targeting attitudes, knowledge, and skills related to sugar-sweetened beverage and water consumption. Parent participants will be exposed to intervention messages (e.g., reduce SSB intake) through weekly parent-child take-home activities, child sharing of narratives produced, and a culminating open house event.
Study NCT03730623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Description: Supervised exercise training as a conservative management of intermittent claudication in a community setting based on cardiac rehabilitation program
Study NCT00881374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Dermacyd Infantile (Lactic Acid)
Study NCT01143129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Single dose (1 mg/kg) at start of cardiac surgical procedure
Study NCT01143129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution in a comparable amount to the experimental drug (0.05 mL/kg)
Study NCT02068001 — intervention group
Intervention type: PROCEDURE
Intervention: Roux-en-Y Gastric Bypass
Study NCT02007798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 2 ml of dexmedetomidine at a concentration of 100 ug/ml is diluted by 98 ml normal saline to a concentration of 2 ug/ml. The required amount of experimental drugs is confirmed according to the weight and grouping, and diluted using normal saline to 20 ml.
Study NCT02007798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: 100 ml per bag
Study NCT02967367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BodyMedia Sense Wear accelerometer
Description: During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
Study NCT03993938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVI measurement
Description: Masimo Radical-7® probe to be attached to patient's finger along with standard ASA monitors at the start of procedure. After placement of arterial line, stroke volume variation (SVV) and pulse pressure variation (PPV) to be recorded along with pleth variability index (PVI) every 5 minutes. Intraprocedure left atrial pressure (LAP) (v-wave and mean) to be recorded prior to and after MitraClip deployment. Data to be analyzed - age, sex, BMI; Preprocedure ejection fraction (EF), pulmonary artery pressure (PAP), rhythm, mitral regurgitation severity; heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) every 5 minutes; SVV, PPV, PVI every 5 minutes; LAP prior to mitraclip deployment; LAP after mitraclip deployment
Study NCT01399593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Study NCT01563068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% Foam
Description: Topical application applied twice a day for 15 days
Study NCT00009919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Description: Given IV
Study NCT02378766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website A
Description: Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé (TAVIE : Traitement, Assistance Virtuelle Infirmière et Enseignement).~TAVIE en santé is a web-based tailored multicomponent intervention addressing smoking cessation, physical activity and healthy eating. Each component consists of seven interactive computer sessions lasting 5-10 minutes. The sessions, hosted by a virtual nurse, aims to develop and strengthen skills required for behavior change.
Study NCT02378766 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Website B
Description: Patients assigned to this arm will be invited to consult a validated list of five predetermined websites offering information about the health behavior they chose: being physically active, following a healthy diet or quitting smoking. These websites offers reliable information and their content were validated by experts.
Study NCT02437565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stainless steel crown
Description: Placement of stainless steel crowns for teeth that have undergone pulpotomy for the treatment of pulpitis induced by severe early childhood caries under general anesthesia
Study NCT02437565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stainless steel crown
Description: Placement of stainless steel crowns for teeth that have undergone pulpotomy for the treatment of pulpitis induced by severe early childhood caries under general anesthesia
Study NCT02437565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occlusal Template
Description: Use of an occlusal template for the placement of stainless steel crowns under general anesthesia
Study NCT01393769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: The usual number of chemotherapy cycles will be 3. First treatment with Melphalan will be initiated as soon as possible, once the patients are selected for the study. Once the first treatment has been completed, day 0, successive treatments will be considered, second and third (days 21 and 42). In those cases in which some patients could be considered for an additional treatments after the third cycle, these will be administrated in intervals at least of 21 days.Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume.
Study NCT04689126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical or nonsurgical endodontic treatment
Description: Change in diagnosis and treatment plans between the two imaging - periapical radiography and cone beam computed tomography
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IIGI+GIP
Description: Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+GIP
Description: Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
Study NCT04317248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous drip，250mg/m\^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）
Study NCT04317248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple Signals loaded Dendritic Cells Vaccine
Description: one time every 4 weeks during 0 weeks to 20 weeks, about 5\*10\^7 cells per time, intravenous driptotal 6 times;
Study NCT05149417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS reminding
Description: patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .
Study NCT05149417 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: telemonitoring
Description: Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
Study NCT05149417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: telemonitoring
Description: Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
Study NCT02099214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3Tesla cardiac MRI
Study NCT02099214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram (EKG)
Study NCT02099214 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iron and cardiac markers
Description: Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP
Study NCT02099214 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pregnancy test
Description: Beta-hCG
Study NCT02099214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiography at rest
Description: Transthoracic echocardiograph
Study NCT02099214 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urinary pregnancy test
Study NCT02099214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3Tesla abdominal MRI
Study NCT02499393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: intravenous infusion of magnesium sulphate
Study NCT02311751 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
Study NCT02311751 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
Study NCT01955070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia Presentation for Ketamine sedation
Description: PowerPoint presentation created with approval of section of emergency medicine for informed consent for ketamine sedation
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IIGI+GIP
Description: Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IIGI+GLP-1
Description: glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
Study NCT03595878 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Parotid sparing WBRT
Description: Whole Brain Radiation Therapy with avoidance of the parotid glands
Study NCT03595878 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard WBRT
Description: Standard Whole Brain Radiation Therapy
Study NCT03869593 — intervention group
Intervention type: GENETIC
Intervention: Sample analysis
Description: Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
Study NCT00557791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevasiranib
Description: Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
Study NCT00557791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
Study NCT04349722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine Butylbromide
Description: Intervention is given once a participant is in established labor
Study NCT04349722 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention is given once a participant is in established labor
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+GLP-1
Description: glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IIGI+GLP-1
Description: glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IIGI+NaCl (placebo)
Description: i.v. NaCl during isoglycemia
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+NaCl (placebo)
Description: i.v. NaCl during isoglycemia
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IIGI+NaCl (placebo)
Description: i.v. NaCl during isoglycemia
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: OGTT
Description: 50 g oral glucose tolerance test
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: 50 g oral glucose tolerance test
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: OGTT
Description: 50 g oral glucose tolerance test
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IIGI+GIP+GLP-1
Description: i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+GIP+GLP-1
Description: i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
Study NCT01563263 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC43
Description: 100 mcg
Study NCT01563263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: phosphate buffered saline (PBS) solution containing 0,9 % NaCl
Study NCT00575965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Oral tablets taken daily
Study NCT03712683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyroxine
Description: Thyroxine was prescribed with the diagnosis of SCH and continued when pregnancy was confirmed
Study NCT02598791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IIGI+GIP+GLP-1
Description: i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
Study NCT04034329 — intervention group
Intervention type: PROCEDURE
Intervention: ASVAL
Description: Ambulatory Selective Varices Ablation under Local Anesthesia
Study NCT04034329 — intervention group
Intervention type: PROCEDURE
Intervention: EVLA
Description: Endovenous Laser Ablation
Study NCT01469416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg PO x 1
Study NCT01469416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg PO x 1
Study NCT01469416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 300 mg PO x 1 (30 minutes prior to rosuvastatin dose); Clopidogrel 75 mg PO x 1 (24 hours post-rosuvastatin dose)
Study NCT02113904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 6 injections (one every 15 days during 3 months)
Study NCT02783976 — intervention group
Intervention type: DRUG
Intervention: Sovaldi
Description: Sovaldi 400 mg tablets administered orally once daily
Study NCT00879255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy Group In-Person
Description: Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference.
Study NCT03885843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal nerve stimulation, mapping and denervation
Description: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal nerve stimulation, mapping and denervation procedure after randomization.
Study NCT03885843 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure: Renal angiography
Description: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal
Study NCT01043692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
Study NCT02654054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Film-coated tablets
Study NCT02654054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Estradiol/Norethindrone Acetate
Description: Placebo capsules
Study NCT02654054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Estradiol/Norethindrone Acetate
Description: Placebo capsules
Study NCT02654054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/Norethindrone Acetate
Description: Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
Study NCT02618161 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HDR Brachytherapy
Description: HDR Brachytherapy, a single dose of 15 Gy delivered to prostate
Study NCT02618161 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR Brachytherapy
Description: HDR Brachytherapy, a single dose of 15 Gy delivered to prostate
Study NCT02618161 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam Radiotherapy
Description: External beam Radiotherapy, a dose of 46 Gy in 23 fractions delivered to prostate
Study NCT02618161 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam Radiotherapy
Description: External beam Radiotherapy, a dose of 46 Gy in 23 fractions delivered to prostate
Study NCT02301949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Patients are randomly assigned to receive a second course of four-month treatment of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China). Medications are taken orally 25mg four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
Study NCT02301949 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients are randomly assigned to receive placebo tablets (Pharmaceutical Co., Ltd. of ChangZhou, China) four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
Study NCT04327947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid - Research product 1
Description: Health care product (intimate gel)
Study NCT04327947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid - Research product 1
Description: Health care product (intimate gel)
Study NCT04327947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid - Research product 2
Description: Health care product (intimate gel)
Study NCT04327947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid - Research product 2
Description: Health care product (intimate gel)
Study NCT04327947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid - Comparator product
Description: Health care product (intimate gel)
Study NCT04327947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid - Comparator product
Description: Health care product (intimate gel)